Genetic Replacement of the Adenovirus Shaft Fiber Reduces Liver Tropism in Ovarian Cancer Gene Therapy

Human Gene Therapy

Volumn 15, Issue 5, 2004, Pages 509-518

  Breidenbach, Martina ^a   Rein, Daniel T ^a   Wang, Minghui ^a   Nettelbeck, Dirk M ^c   Hemminki, Akseli ^d,e   Ulasov, Ilya ^a   Rivera, Angel R ^a   Everts, Maaike ^a   Alvarez, Ronald D ^b   Douglas, Joanne T ^a   Curiel, David T ^a,f  

^a Division of Human Gene Therapy   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; INTEGRIN; RECOMBINANT PROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; CANCER CELL; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TARGETING; FEMALE; GENE REPLACEMENT THERAPY; GENE TARGETING; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER STRUCTURE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; OVARY CANCER; OVARY CELL; PLANT GROWTH; SEROTYPE; TUMOR; TUMOR GROWTH; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRUSES, HUMAN; ANIMALS; CELL LINE, TUMOR; EPITHELIAL CELLS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LIVER; LUCIFERASES; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; SEROTYPING; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS; FALLOPIA; HUMAN ADENOVIRUS TYPE 5;

EID: 2442544553     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340460745829     Document Type: Article

References (42)

1. AKIYAMA, M., THORNE, S., KIRN, D., ROELVINK, P.W., EINFELD, D.A., KING, C.R., and WICKHAM, T.J. (2004). Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. Mol. Ther. 9, 218-230.
2. ALEMANY, R., and CURIEL, D.T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8, 1347-1353.
3. ANDERS, M., HANSEN, R., DING, R.X., RAUEN, K.A., BISSELL, M.J., and KORN, W.M. (2003). Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc. Natl. Acad. Sci. U.S.A. 100, 1943-1948.
4. BARKER, S.D., CASADO, E., GOMEZ-NAVARRO, J., XIANG, J., ARAFAT, W., MAHASRESHTI, P., PUSTILNIK, T.B., HEMMINKI, A., SIEGAL, G.P., ALVAREZ, R.D., and CURIEL, D.T. (2001). An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol. Oncol. 82, 57-63.
5. BAUERSCHMITZ, G.J., LAM, J.T., KANERVA, A., SUZUKI, K., NETTELBECK, D.M., DMITRIEV, I., KRASNYKH, V., MIKHEEVA, G.V., BARNES, M.N., ALVAREZ, R.D., DALL, P., ALEMANY, R., CURIEL, D.T., and HEMMINKI, A. (2002). Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 62, 1266-1270.
6. CRIPE, T.P., DUNPHY, E.J., HOLUB, A.D., SAINI, A., VASI, N.H., MAHLLER, Y.Y., COLLINS, M.H., SNYDER, J.D., KRASNYKH, V., CURIEL, D.T., WICKHAM, T.J., DEGREGORI, J., BERGELSON, J.M., and CURRIER, M.A. (2001). Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus- adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61, 2953-2960.
7. DMITRIEV, I., KRASNYKH, V., MILLER, C.R., WANG, M., KASHENTSEVA, E., MIKHEEVA, G., BELOUSOVA, N., and CURIEL, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713.
8. DMITRIEV, I., KASHENTSEVA, E., ROGERS, B.E., KRASNYKH, V., and CURIEL, D.T. (2000). Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 74, 6875-6884.
9. EINFELD, D.A., SCHROEDER, R., ROELVINK, P.W., LIZONOVA, A., KING, C.R., KOVESDI, I., and WICKHAM, T.J. (2001). Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75, 11284-11291.
10. FECHNER, H., HAACK, A., WANG, H., WANG, X., EIZEMA, K., PAUSCHINGER, M., SCHOEMAKER, R., VEGHEL, R., HOUTSMULLER, A., SCHULTHEISS, H.P., LAMERS, J., and POLLER, W. (1999). Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6, 1520-1535.
11. FECHNER, H., WANG, X., WANG, H., JANSEN, A., PAUSCHINGER, M., SCHERUBL, H., BERGELSON, J.M., SCHULTHEISS, H.P., and POLLER, W. (2000). Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther. 7, 1954-1968.
12. HASENBURG, A., FISCHER, D.C., TONG, X.W., ROJAS-MARTINEZ, A., KAUFMAN, R.H., RAMZY, I., KOHLBERGER, P., ORLOWSKA-VOLK, M., AGUILAR-CORDOVA, E., and KIEBACK, D.G. (2002). Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: Expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5. J. Soc. Gynecol. Investig. 9, 174-180.
13. HEISE, C.C., WILLIAMS, A.M., XUE, S., PROPST, M., and KIRN, D.H. (1999). Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59, 2623-2628.
14. HEMMINKI, A. (2002). From molecular changes to customised therapy. Eur. J. Cancer 38, 333-338.
15. HEMMINKI, A., BELOUSOVA, N., ZINN, K.R., LIU, B., WANG, M., CHAUDHURI, T.R., ROGERS, B.E., BUCHSBAUM, D.J., SIEGAL, G.P., BARNES, M.N., GOMEZ-NAVARRO, J., CURIEL, D.T., and ALVAREZ, R.D. (2001). An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol. Ther. 4, 223-231.
16. HUARD, J., LOCHMULLER, H., ACSADI, G., JANI, A., MASSIE, B., and KARPATI, G. (1995). The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2, 107-115.
17. JEMAL, A., MURRAY, T., SAMUELS, A., GHAFOOR, A., WARD, E., and THUN, M.J. (2003). Cancer statistics, 2003. CA Cancer J. Clin. 53, 5-26.
18. KANERVA, A., MIKHEEVA, G.V., KRASNYKH, V., COOLIDGE, C.J., LAM, J.T., MAHASRESHTI, P.J., BARKER, S.D., STRAUGHN, M., BARNES, M.N., ALVAREZ, R.D., HEMMINKI, A., and CURIEL, D.T. (2002a). Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8, 275-280.
19. KANERVA, A., WANG, M., BAUERSCHMITZ, G.J., LAM, J.T., DESMOND, R.A., BHOOLA, S.M., BARNES, M.N., ALVAREZ, R.D., SIEGAL, G.P., CURIEL, D.T., and HEMMINKI, A. (2002b). Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5, 695-704.
20. KASS-EISLER, A., FALCK-PEDERSEN, E., ELFENBEIN, D.H., ALVIRA, M., BUTTRICK, P.M., and LEINWAND, L.A. (1994). The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1, 395-402.
21. KELLY, F.J., MILLER, C.R., BUCHSBAUM, D.J., GOMEZ-NAVARRO, J., BARNES, M.N., ALVAREZ, R.D., and CURIEL, D.T. (2000). Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin. Cancer Res. 6, 4323-4333.
22. KIM, M., ZINN, K.R., BARNETT, B.G., SUMEREL, L.A., KRASNYKH, V., CURIEL, D.T., and DOUGLAS, J.T. (2002). The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur. J. Cancer 38, 1917-1926.
23. KIRN, D., MARTUZA, R.L., and ZWIEBEL, J. (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7, 781-787.
24. KOIZUMI, N., MIZUGUCHI, H., SAKURAI, F., YAMAGUCHI, T., WATANABE, Y., and HAYAKAWA, T. (2003). Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J. Virol. 77, 13062-13072.
25. KRASNYKH, V.N., MIKHEEVA, G.V., DOUGLAS, J.T., and CURIEL, D.T. (1996). Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 70, 6839-6846.
26. LAM, J.T., BAUERSCHMITZ, G.J., KANERVA, A., BARKER, S.D., STRAUGHN, J.M., WANG, M., BARNES, M.N., BLACKWELL, J.L., SIEGAL, G.P., ALVAREZ, R.D., CURIEL, D.T., and HEMMINKI, A. (2003). Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther. 10, 377-387.
27. LI, Y., PONG, R.C., BERGELSON, J.M., HALL, M.C., SAGALOWSKY, A.I., TSENG, C.P., WANG, Z., and HSIEH, J.T. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 59, 325-330.
28. LIEBER, A., HE, C.Y., MEUSE, L., SCHOWALTER, D., KIRILLOVA, I., WINTHER, B., and KAY, M.A. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71, 8798-8807.
29. NAKAMURA, T., SATO, K., and HAMADA, H. (2003). Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J. Virol. 77, 2512-2521.
30. NEMEROW, G.R., and STEWART, P.L. (1999). Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol. Mol. Biol. Rev. 63, 725-734.
31. REYNOLDS, P., DMITRIEV, I., and CURIEL, D. (1999). Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther. 6, 1336-1339.
32. SHAYAKHMETOV, D.M., and LIEBER, A. (2000). Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol. 74, 10274-10286.
33. SHAYAKHMETOV, D.M., LI, Z.Y., NI, S., and LIEBER, A. (2002). Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. 62, 1063-1068.
34. SMITH, T.A., IDAMAKANTI, N., MARSHALL-NEFF, J., ROLLENCE, M.L., WRIGHT, P., KALOSS, M., KING, L., MECH, C., DINGES, L., IVERSON, W.O., SHERER, A.D., MARKOVITS, J.E., LYONS, R.M., KALEKO, M., and STEVENSON, S.C. (2003a). Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther. 14, 1595-1604.
35. SMITH, T.A., IDAMAKANTI, N., ROLLENCE, M.L., MARSHALLNEFF, J., KIM, J., MULGREW, K., NEMEROW, G.R., KALEKO, M., and STEVENSON, S.C. (2003b). Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 14, 777-787.
36. TAO, N., GAO, G.P., PARR, M., JOHNSTON, J., BARADET, T., WILSON, J.M., BARSOUM, J., and FAWELL, S.E. (2001). Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3, 28-35.
37. VANDERKWAAK, T.J., WANG, M., GOMEZ-NAVARRO, J., RANCOURT, C., DMITRIEV, I., KRASNYKH, V., BARNES, M., SIEGAL, G.P., ALVAREZ, R., and CURIEL, D.T. (1999). An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol. Oncol. 74, 227-234.
38. VIGNE, E., DEDIEU, J.F., BRIE, A., GILLARDEAUX, A., BRIOT, D., BENIHOUD, K., LATTA-MAHIEU, M., SAULNIER, P., PERRICAUDET, M., and YEH, P. (2003). Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther. 10, 153-162.
39. WOOD, M., PERROTTE, P., ONISHI, E., HARPER, M.E., DINNEY, C., PAGLIARO, L., and WILSON, D.R. (1999). Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther. 6, 367-372.
40. WU, H., DMITRIEV, I., KASHENTSEVA, E., SEKI, T., WANG, M., and CURIEL, D.T. (2002). Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J. Virol. 76, 12775-12782.
41. ZEIMET, A.G., MULLER-HOLZNER, E., SCHULER, A., HARTUNG, G., BERGER, J., HERMANN, M., WIDSCHWENDTER, M., BERGELSON, J.M., and MARTH, C. (2002). Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther. 9, 1093-1100.
42. ZHANG, Y., CHIRMULE, N., GAO, G.P., QIAN, R., CROYLE, M., JOSHI, B., TAZELAAR, J., and WILSON, J.M. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3, 697-707.